KGC awarded for ginseng research at US expo
According to the company, the award, presented by the American Botanical Council in recognition of outstanding contributions to the field of herbal medicine and pharmacognosy, honors its commitment to proving the health benefits of ginseng through clinical research.
The ABC is a nonprofit organization dedicated to providing reliable information on herbs and medicinal plants to consumers, healthcare practitioners and researchers.
'We are deeply honored that our decades of research and development have been recognized by such a respected institution,' a company researcher said upon receiving the award, vowing to further advance and globalize Korean health supplements.
KGC has consistently advanced research and development in red ginseng and other health ingredients, earning key recognitions. Notably, it received certification from the Ministry of Food and Drug Safety for verifying red ginseng's benefits in regulating blood sugar levels and supporting prostate health.
To further efficacy research and develop products tailored for global consumers, KGC established a research and development center in Shanghai, China, in 2013, followed by another in Los Angeles, US, in March 2023. These centers continue to explore the benefits of red ginseng and other health ingredients.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
9 hours ago
- Korea Herald
Korea urges measles vaccination before overseas travel as imported cases rise
Amid a sharp rise in imported cases of measles recently, the Korea Disease Control and Prevention Agency has urged travelers to ensure they are fully vaccinated against the infectious disease before going abroad. According to KDCA data released Wednesday, 68 cases of measles had been confirmed in Korea as of Aug. 9, since the government began to closely observe outbreak cases in December 2024. The number of cases observed most recently was a 1.4-fold increase from the number of cases recorded over the same period a year prior. Of the total number of cases, 49 — 72.1 percent — were infections contracted overseas and detected after entry. A majority of the cases, adding up to 42 in total, were found to be contracted from Vietnam, followed by South Africa, Uzbekistan, Thailand, Italy and Mongolia. The nineteen other domestic cases were also linked to these imported infections, with transmission occurring in households and medical facilities with measles patients. Adults made up a majority of the cases, with 77.9 percent of patients aged 19 or older. Notably, 54.4 percent were either unvaccinated against measles or were unsure of their vaccination status. Citing data from the World Health Organization, the KDCA said some 360,000 measles cases were reported globally in 2024, with outbreaks still continuing to be observed into this year in Europe, the Middle East, Africa and Southeast Asia — regions all frequented by Korean travelers. According to the agency, lower vaccination rates for measles worldwide have fueled the resurgence. Due to the COVID-19 pandemic, measles vaccinations were disrupted due to a strain in the health care system as well as lockdowns that made it difficult for some families to access vaccination services. In 2023, the global rate of the second-dose measles vaccination — which is crucial for full immunity — was 74 percent, below the WHO-recommended 95 percent. To stay safe from measles infections, the KDCA has advised travelers to measles-affected countries to complete the two-dose measles, mumps and rubella vaccine. Those developing a fever or a rash within three weeks of returning to South Korea from a measles-affected country should wear a mask, minimize contact with others and inform medical authorities of recent travel before seeking care. Extra caution is urged for households with infants too young for vaccination, pregnant women and those with weakened immune systems.
Korea Herald
12 hours ago
- Korea Herald
HLB appoints Brian Kim as CEO of US subsidary Elevar Therapeutics
Korean biopharmaceutical firm HLB said Wednesday it has appointed Brian Kim, current CEO of HLB Innovation and Verismo Therapeutics, as CEO of its US subsidiary, Elevar Therapeutics. Kim will lead all three companies concurrently. HLB said the leadership change is a strategic move to align with the skills needed at each stage of drug development, particularly as Elevar prepares to enter the commercialization phase and expand global partnerships with big pharma. Kim holds extensive experience in finance, strategic business management and biotechnology, including research in CAR-T cancer treatments and founding multiple biotech firms. A former tenured clinical professor at the University of Pennsylvania School of Dental Medicine, Kim was a founding member of Nasdaq-listed Inovio Pharmaceuticals. He has invested in various businesses, including acquiring a Kospi-listed company and elevating it into the Kospi 200 index. Kim also has invested in and led several biotech ventures in both the US and Korea. 'I feel a deep sense of responsibility taking on this role at such a pivotal moment,' Kim said. 'My focus will be on securing regulatory approval for Elevar's lead liver cancer therapy and ensuring its successful commercialization, while driving sustainable growth for the company.' HLB added that Kim's leadership will help accelerate Elevar's global business expansion and innovation in oncology therapeutics.
Korea Herald
a day ago
- Korea Herald
Celltrion expands presence in Italy with autoimmune, anticancer drugs
Korean biopharma scores seven contracts in first half of 2025 in major European market Celltrion has won bids to supply its autoimmune drug Steqeyma in seven states in Italy in the first half of this year to expand its presence in the country, the Korean biopharmaceutical company said Tuesday. According to Celltrion, it recently won the bids for autoimmune medicine in Veneto, Trentino-Alto Adige and Sardinia. The drug maker said it plans to supply Steqeyma to these regions through May. Celltrion pointed out that the drug rapidly secured contracts after launching in Italy in January. Remsima, Celltrion's flagship autoimmune drug, also continues to secure orders in Italy as it won a bid in the state of Umbria, while Remsima SC was able to renew a contract with Puglia. According to Celltrion, Remsima SC is being sold in all 20 states in Italy. Medicine market analyst IQVIA estimates that Remsima and Remsima SC combined for 66 percent of the Italian autoimmune drug market in the first quarter. Celltrion's anticancer drugs Truxima and Vegzelma won the bids in the states of Lazio and Umbria, respectively, earlier in the year, taking up 29 percent and 30 percent of the market. The company said it expects to keep supplying anticancer drugs in Italy as more bids are scheduled in the second half of the year. 'Based on high trust from major stakeholders in Italy's medical industry, a key pharmaceutical market in Europe, Celltrion's autoimmune treatments and anticancer drugs are expanding influence by logging a series of orders,' said Yoo Won-sik, general manager of Celltrion's Italian office. 'We will continue to launch new products and score more orders in the second half to expand the prescription of our products and keep up the growth of performance.'
